Rezūm™ Treatment for BPH

Rezūm™ is a minimally invasive alternative to BPH medications that relieves symptoms safely and effectively with minimal side effects.

Rezūm™ Treatment for BPH

Office Hours



RezūmRezūm™ is a minimally invasive alternative to BPH medications that relieves symptoms safely and effectively1 in an office or out-patient setting, with minimal side effects. The procedure is done during one visit, patients return to activities within a few days1 and it is considered medically necessary by Medicare and most private insurance*.

Rezūm™ uses the natural energy stored in water vapor, or steam, to treat the extra prostate tissue that is causing the BPH symptoms. The water vapor is delivered into the targeted prostate tissue and when the vapor contacts the tissue it turns back into water, releasing all the stored energy, causing the prostate cells to die.

Over time, the body’s natural healing response removes the dead cells, shrinking the prostate. With the extra tissue removed, the urethra opens, reducing BPH symptoms. Most patients begin to experience symptom relief in as soon as two weeks and maximum benefit will occur within three months.

To learn more, visit


Currently, the most common surgery to treat BPH is Transurethral Resection of the Prostate (TURP). During this procedure, patients undergo general anesthesia, and prostate tissue is removed. Patients may suffer an uncomfortable recovery period that includes short-term problems such as bleeding, infection, erectile dysfunction, and urinary incontinence. Patients have to have a catheter that is attached to a urine bag inserted into their bladder for several days after the procedure. There can be long-term side effects after TURP such as dry orgasm (retrograde ejaculation), erectile dysfunction or incontinence (leaking of urine).

*our office will verify coverage with your insurance prior to your treatment.


  1. Roehrborn CG, Gange SN, Gittelman MC et al: Convective Thermal Therapy: Durable 2-Year Results of Randomized Controlled and Prospective Crossover Studies for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. J Urol 2017;197:1507-1516.